Acquisition by AstraZeneca Caelum Research Corporation was recently acquired by AstraZeneca for $150M, indicating potential synergies and opportunities within the pharmaceutical and healthcare sectors where AstraZeneca operates.
Funding Boost and Clinical Trials With recent financing of $60M and plans to initiate two registration clinical trials, Caelum Research Corporation is poised for expansion, presenting opportunities for technology partnerships and service collaborations.
Revenue Range and Business Expansion Operating in the revenue range of $10M - 50M, Caelum Research Corporation displays stability and growth potential, making them an attractive target for complementary service offerings and cross-selling opportunities.
IT Services and Consulting Expertise As an IT services and consulting firm, Caelum Research Corporation brings expertise in areas like Applied Sciences, Information Technology, and System Engineering, opening doors for collaboration in projects involving cutting-edge technologies.
Industry Landscape and Competitor Analysis In a sector with players like Viasat, CACI INTERNATIONAL, and MicroHealth LLC, Caelum Research Corporation stands out with its niche offerings, presenting a competitive advantage and strategic alliance possibilities.